Table of Contents Table of Contents
Previous Page  144 / 916 Next Page
Show Menu
Previous Page 144 / 916 Next Page
Page Background


25th European Congress of Psychiatry / European Psychiatry 41S (2017) S106–S169


Targeting kynurenine pathway in

olfactory bulbectomised mice:

Inflammatory and neurodegerative

pathway of depression

Y. Bansal

, A. Kuhad , R. Singh , P. Saroj

Pharmacology Lab, Panjab University, University Institute of

Pharmaceutical Sciences, Chandigarh, India

Corresponding author.

Aims and objectives

The aim of study was to evaluate the phar-

macotherapeutic efficacy of NDGA in experimental paradigm of

depression i.e. olfactory bulbectomy (OB) specifically targeting

kynurenine pathway.

Materials and method

Depression like behaviours was induced

in OB mice and evaluated by assessment of various behavioural

(olfactory deficit test, forced swim test, splash test, open field

test, sucrose preference test), biochemical (catalase, reduced glu-

tathione, SOD, nitrite, MAO-A, MDA, corticosterone), inflammatory

cytokines (TNF- , IL-1 , IL-6, IFN- ) levels and alterations in delta

sleep was recorded using EEG. Kynurenine pathway metabolites

were determined in plasma and brain using HPLC method. After

14 days post-surgery, olfactory bulbectomized (OBX) mice were

administered nordihydroguaiaretic acid (5 mg/kg, 10 mg/kg and

25 mg/kg) daily i.p.


We have developed a newHPLCmethod for simultaneous

estimation of monoamines and kynurenine pathway metabolites

in plasma and brain samples of mice. Chronic treatment with

nordihydroguaiaretic acid significantly restored all behavioural,

biochemical and neurochemical alterations in OBX mice and

increase in quinolinic acid and decrease in kynurenic acid point

out the neurodegeneration hypothesis of depression.


Nordihydroguaiaretic acid showed potent neu-

ropharmacotherapeutic effect in OBX mice by virtue of its

strong anti-oxidant, anti-inflammatory, anti-stress and by restor-

ing quinolinic acid levels.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Prefrontal theta cordance in the

prediction of antidepressant response

to various classes of antidepressants

in patients with depressive disorder

M. Bares

1 ,

, T. Novak


, M. Brunovsky


, M. Hejzlar



2nd Department, National Institute of Mental Health Czech

Republic, Klecany, Czech Republic


EEG Department, National Institute of Mental Health Czech

Republic, Klecany, Czech Republic

Corresponding author.

Introduction and objectives

Previous studies demonstrated effi-

cacy of reduction of QEEG prefrontal theta cordance (RC) after

the first week of treatment in the prediction of antidepressant



The study aimed to compare the ability of RC in the predic-

tion of response to various antidepressant classes.


All patients (


= 142) were treated with antidepressants

(SSRI-58, SNRI-47, NDRI-22, NaSSA-15) for

4 weeks. Response

was defined as MADRS reduction

50%. EEG were performed at

baseline and week 1 of treatment and cordance was calculated for

3 prefrontal electrodes (Fp1, Fp2, Fz).


Logistic regression identified RC as a predictor of

response to SSRI, SNRI and NDRI but not for NaSSA. Predictive

parameters of RC for response to mentioned antidepressant classes

are displayed in the

Table 1 .

Areas under curves of ROC analysis (AUC) of RC for response predic-

tion were not significantly different among antidepressant classes.


The predictive efficacy of RC for response to SSRI, SNRI

and NDRI was comparable.

This study was supported by the grants of MH CZ nr.15-29900A,

MH CZ – DRO (NIMH-CZ, 00023752) and by the project Nr. LO1611

from the MEYS under the NPU I program.

Table 1








AUC RC week 1


0.77 (0.65–0.87) 0.77 (0.62–0.88) 0.87 (0.66–0.97)

Positive predictive

value of RC

week 1 (95%CI)

0.81 (0.64–0.93) 0.72 (0.51–0.87) 0.91 (0.59–1.00)



values of RC

week 1 (95%CI)

0.73 (0.52–0.89) 0.84 (0.60–0.97) 0.82 (0.48–0.98)

Accuracy of





Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Major depressive disorder:

Recurrence risk factors

R. Ben Soussia

, S. Khouadja , I. Marrag , S. Younes , M. Nasr

Psychiatry, CHU Tahar Sfar, Mahdia, Tunisia

Corresponding author.


In spite of the frequency and the gravity of the

depressive episodes, the major depressive disorder (MDD) is diag-

nosed and treated today insufficiently and the risk factors of its

recurrence are little approached.

Aims of the study

Describe the socio–demographic, clinical and

therapeutic characteristics of patients with MDD and identify the

factors involved in the recurrence risk.


This is a retrospective study carried out in the uni-

versity hospital of Mahdia, Tunisia during two years. We have

included patients with a follow up for at least two years and

diagnosed with MDD, isolated episode or MDD, recurrent episode

according to the DSM-IV-TR criteria. Data collectionwas performed

using two pre-established questionnaires respectively with 51 and

92 items. We have estimated the time to recurrence with the

Kaplan-Meier estimator.


We have collected 150 patients. The time to recurrence

was 109 months. Five factors were associated with recurrence:

early age at onset of the disorder, family history of mood disorders,

severity of the index major depressive episode, persistent residual

symptoms and ceasing treatment.


Depression is a very common mental illness that

is highly recurrent in individuals. There is great interest in the

development of strategies that might reduce the recurrence of


Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.